EA201791122A1 - Методы лечения отравлений, вызванных укусами ядовитых животных, и соответствующие композиции, системы и комплекты - Google Patents
Методы лечения отравлений, вызванных укусами ядовитых животных, и соответствующие композиции, системы и комплектыInfo
- Publication number
- EA201791122A1 EA201791122A1 EA201791122A EA201791122A EA201791122A1 EA 201791122 A1 EA201791122 A1 EA 201791122A1 EA 201791122 A EA201791122 A EA 201791122A EA 201791122 A EA201791122 A EA 201791122A EA 201791122 A1 EA201791122 A1 EA 201791122A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- poisoning
- inhibitor
- treatment
- antidote
- poison
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Изобретение предусматривает создание методов лечения, фармацевтических композиций, систем и комплектов, приемлемых для первоочередного лечения и(или) вспомогательной терапии с противоядием, используя по меньшей мере один активный компонент, в некоторых случаях по меньшей мере два активных компонента и в других случаях не более двух активных компонентов, выбранных из группы, включающей селективный секреторный ингибитор PLA2 (sPLA2 или ингибитор PLA2), ингибитор металлопротеиназы, ингибитор сериновой протеазы, противоядие, один или более ингибиторов ацетилхолинэстеразы или агонист nAChR, соединенный с антагонистом mAChR, антагонист NMDA рецептора и ингибитор фактора распространения, для лечения субъекта, страдающего от отравлений, вызванных укусами ядовитых животных, предпочтительно в момент отравления, и зачастую в течение периода времени, составляющего менее приблизительно 1 ч после отравления ядом или 6 ч после отравления ядом, и на протяжении всего курса лечения в некоторых случаях с противоядием или без него в качестве вспомогательной терапии после отравления ядом, например, змеи или беспозвоночных.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462082895P | 2014-11-21 | 2014-11-21 | |
US201562131441P | 2015-03-11 | 2015-03-11 | |
US201562243374P | 2015-10-19 | 2015-10-19 | |
PCT/US2015/061834 WO2016081826A2 (en) | 2014-11-21 | 2015-11-20 | Envenomation therapies and related pharmaceutical compositions, systems and kits |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791122A1 true EA201791122A1 (ru) | 2018-04-30 |
EA037262B1 EA037262B1 (ru) | 2021-03-01 |
Family
ID=56014685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791122A EA037262B1 (ru) | 2014-11-21 | 2015-11-20 | Способы лечения отравлений, вызванных укусами ядовитых змей |
Country Status (18)
Country | Link |
---|---|
US (2) | US11000506B2 (ru) |
EP (1) | EP3220902A4 (ru) |
JP (1) | JP6883515B2 (ru) |
KR (1) | KR20170086089A (ru) |
CN (1) | CN107249578B (ru) |
AU (1) | AU2015349774B2 (ru) |
BR (1) | BR112017010495B1 (ru) |
CA (1) | CA2968383C (ru) |
CR (1) | CR20170259A (ru) |
EA (1) | EA037262B1 (ru) |
IL (1) | IL252418B (ru) |
MA (1) | MA40998A (ru) |
MX (1) | MX2017006551A (ru) |
MY (1) | MY187053A (ru) |
PH (1) | PH12017500927A1 (ru) |
SG (1) | SG11201704106VA (ru) |
TW (1) | TWI745280B (ru) |
WO (1) | WO2016081826A2 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786483B2 (en) * | 2016-03-04 | 2020-09-29 | Hk Pharma | Tumescent contravenom drug delivery |
IL307232A (en) | 2016-04-29 | 2023-11-01 | Ophirex Inc | PLA2 and HMG-COA suppressors for the treatment of pathological diseases that cause hemolysis, brain edema and acute kidney injury |
US20200009071A1 (en) * | 2016-12-16 | 2020-01-09 | The Regents Of The University Of California | Neutralizing venomous biomacromolecules |
CN110662548A (zh) * | 2017-02-17 | 2020-01-07 | 卡姆瑞斯国际公司 | 通用抗毒液素 |
CN108703975A (zh) * | 2018-08-30 | 2018-10-26 | 黄汝怡 | 一种治疗毒虫叮咬的涂抹剂 |
CN109260196A (zh) * | 2018-11-08 | 2019-01-25 | 中国科学院海洋研究所 | 巴马司他作为制备水母皮炎药物的应用 |
EP4045026A4 (en) * | 2019-10-15 | 2023-11-08 | Ophirex, Inc. | EARLY MANAGEMENT, MITIGATION AND PREVENTION OF SEPTICEMIA AND SEPTICEMIA-LIKE SYNDROMES, INCLUDING SYNDROMES OF ACUTE RESPIRATORY DISTRESS OF THE NEWBORN DUE TO INFECTION, INJURY OR IATROGENESIS |
CN112494498A (zh) * | 2020-12-11 | 2021-03-16 | 中国人民解放军海军军医大学 | 四环素在制备预防或缓解水母蜇伤药物中的应用 |
WO2022216953A1 (en) * | 2021-04-08 | 2022-10-13 | Believe In A Cure, Inc. | Compounds for use in increasing foxg1 expression |
US20230054792A1 (en) * | 2021-05-14 | 2023-02-23 | Liverpool School Of Tropical Medicine | Methods and compositions for the treatment of snake bite |
CN113817738B (zh) * | 2021-10-20 | 2023-06-16 | 湖南科技学院 | 银杏长链非编码rna及其在银杏内酯生物合成中的应用 |
WO2023086343A1 (en) * | 2021-11-09 | 2023-05-19 | Ophirex, Inc. | Compositions and dosage forms for topical and transdermal delivery of actives and methods of use |
KR20230131139A (ko) | 2022-03-04 | 2023-09-12 | 한국원자력의학원 | 다라플라딥 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 방사선 조사에 의한 피부질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196193A (en) | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
CN1067054C (zh) | 1994-04-01 | 2001-06-13 | 伊莱利利公司 | 1H-吲哚-3-乙醛酰胺sPLA2抑制剂 |
AUPP076797A0 (en) | 1997-12-05 | 1998-01-08 | Active (Pla) R&D Pty Ltd | Phospholipase inhibitor |
AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
DK1613297T3 (da) | 2003-04-14 | 2007-09-24 | Lohmann Therapie Syst Lts | Terapeutisk plaster med polysiloxanmatrix indeholdende capsaicin |
US20070093518A1 (en) | 2003-09-19 | 2007-04-26 | Wetherell Janet R | Pharmaceutical compositions for the treatment of organophosphate poisoning |
WO2005041960A2 (en) | 2003-10-28 | 2005-05-12 | Cornell Research Foundation, Inc. | Neuromuscular blocking agents and antagonists thereof |
US20090012067A1 (en) | 2005-02-14 | 2009-01-08 | Luciano Rossetti | Modulation of Hypothalamic Atp-Sensitive Potassium Channels |
ES2413056T3 (es) | 2005-10-12 | 2013-07-15 | Advanced Accelerator Applications | Antagonista del péptido receptor Alfavbeta3 selectivo para aplicaciones terapéuticas y de diagnóstico |
EP2069377A4 (en) | 2006-09-27 | 2009-11-11 | Univ California | METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS |
US20090062369A1 (en) * | 2007-08-31 | 2009-03-05 | Joaquim Trias | Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels |
WO2009047762A1 (en) * | 2007-10-09 | 2009-04-16 | Yeda Research And Development Co. Ltd | Compositions and peptides for treatment of envenomation by pla2 containing venoms like bungarus multicinct venom |
CN101977626A (zh) | 2008-01-21 | 2011-02-16 | 德莫迪斯公司 | 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 |
CA2751884C (en) | 2009-01-14 | 2018-09-25 | Corium International, Inc. | Transdermal administration of tamsulosin |
US20120232031A1 (en) | 2009-10-19 | 2012-09-13 | Panmira Pharmaceuticals, Llc | Injectable formulations for intra-articular or peri-articular administration |
US20130253060A1 (en) * | 2011-09-21 | 2013-09-26 | Harihara M. Mehendale | Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) |
US9795773B2 (en) | 2011-12-16 | 2017-10-24 | Indosys Limited | Medicament unit dose cartridge and delivery device |
WO2014039920A1 (en) * | 2012-09-10 | 2014-03-13 | Lewin Matthew R | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
US20140087003A1 (en) * | 2012-09-21 | 2014-03-27 | Ignacio Cisneros | Method for treating venomous bites and stings |
-
2015
- 2015-11-19 MA MA040998A patent/MA40998A/fr unknown
- 2015-11-20 CR CR20170259A patent/CR20170259A/es unknown
- 2015-11-20 CA CA2968383A patent/CA2968383C/en active Active
- 2015-11-20 MY MYPI2017701802A patent/MY187053A/en unknown
- 2015-11-20 TW TW104138525A patent/TWI745280B/zh active
- 2015-11-20 JP JP2017527341A patent/JP6883515B2/ja active Active
- 2015-11-20 US US15/528,418 patent/US11000506B2/en active Active
- 2015-11-20 BR BR112017010495-4A patent/BR112017010495B1/pt active IP Right Grant
- 2015-11-20 MX MX2017006551A patent/MX2017006551A/es unknown
- 2015-11-20 EP EP15862088.0A patent/EP3220902A4/en active Pending
- 2015-11-20 CN CN201580074084.6A patent/CN107249578B/zh active Active
- 2015-11-20 EA EA201791122A patent/EA037262B1/ru unknown
- 2015-11-20 AU AU2015349774A patent/AU2015349774B2/en active Active
- 2015-11-20 WO PCT/US2015/061834 patent/WO2016081826A2/en active Application Filing
- 2015-11-20 SG SG11201704106VA patent/SG11201704106VA/en unknown
- 2015-11-20 KR KR1020177016916A patent/KR20170086089A/ko not_active IP Right Cessation
-
2017
- 2017-05-19 PH PH12017500927A patent/PH12017500927A1/en unknown
- 2017-05-21 IL IL252418A patent/IL252418B/en active IP Right Grant
-
2021
- 2021-03-29 US US17/215,466 patent/US20210260029A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112017010495B1 (pt) | 2023-12-05 |
US20170354642A1 (en) | 2017-12-14 |
EA037262B1 (ru) | 2021-03-01 |
WO2016081826A3 (en) | 2016-07-14 |
PH12017500927A1 (en) | 2017-11-20 |
CR20170259A (es) | 2017-10-02 |
EP3220902A2 (en) | 2017-09-27 |
MA40998A (fr) | 2017-09-26 |
AU2015349774B2 (en) | 2020-07-02 |
CA2968383C (en) | 2024-03-12 |
MX2017006551A (es) | 2018-01-15 |
IL252418B (en) | 2021-01-31 |
US20210260029A1 (en) | 2021-08-26 |
TWI745280B (zh) | 2021-11-11 |
CN107249578B (zh) | 2021-01-26 |
CA2968383A1 (en) | 2016-05-26 |
IL252418A0 (en) | 2017-07-31 |
CN107249578A (zh) | 2017-10-13 |
JP2017536372A (ja) | 2017-12-07 |
MY187053A (en) | 2021-08-27 |
SG11201704106VA (en) | 2017-06-29 |
US11000506B2 (en) | 2021-05-11 |
AU2015349774A1 (en) | 2017-06-01 |
EP3220902A4 (en) | 2018-11-07 |
TW201632204A (zh) | 2016-09-16 |
WO2016081826A2 (en) | 2016-05-26 |
KR20170086089A (ko) | 2017-07-25 |
JP6883515B2 (ja) | 2021-06-09 |
BR112017010495A2 (pt) | 2018-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791122A1 (ru) | Методы лечения отравлений, вызванных укусами ядовитых животных, и соответствующие композиции, системы и комплекты | |
EA201391755A1 (ru) | Анти-kir антитела для лечения воспалительных заболеваний | |
EA201891087A1 (ru) | Ингибиторы ret | |
EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
EA201792047A1 (ru) | Новые соединения | |
MY196474A (en) | [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds | |
EA202091484A1 (ru) | 4-азаиндольные соединения | |
EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
EA201790108A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
EA201491918A1 (ru) | Соединения - двойные агонисты gip-glp-1 и способы | |
EA201490545A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
EA201790950A1 (ru) | Способы и композиции, в частности, для лечения синдрома дефицита внимания | |
EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
EA201791579A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2 адренергических рецепторов | |
EA201890800A1 (ru) | Соединения и композиции для лечения глазных расстройств |